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Abstract
Background: NAD-glycohydrolase (NADase) secreted by M-1 group A streptococcal (GAS) isolates are suspected as 
one of the virulence factors to cause severe invasive disease including streptococcal toxic shock-like syndrome (STSS). 
M-1 GAS strains were divided into three groups based on NADase activity: high activity, low activity and no activity in 
our previous report.
Results: The representative high activity isolates taken from STSS patients showed higher virulence compared with 
isolates from the low activity group, when used to infect mice. The knockout mutant of the nga gene, which encodes 
NADase also showed reduced virulence in a mouse infection study. The cloned nga gene was able to significantly 
complement the lost virulence. In addition, the solution containing purified recombinant IFS, which is an inhibitor of 
NADase, partially rescued mice infected with S. pyogenes.
Conclusions: These results indicate that NADase is important for the virulence of S. pyogenes in vivo and is the 
potential target to suppress the virulence.
Background
Group A streptococcus (GAS) is a gram-positive bacte-
rium that infects the upper respiratory tract, including
the tonsils and pharynx, and is responsible for post-infec-
tious diseases such as rheumatic fever and glomerulone-
phritis. In addition, GAS causes severe invasive disease
including necrotizing fasciitis [1-6].
Although the mechanism of severe invasive disease is
still unknown, NAD-glycohydrolase (NADase) secreted
by GAS is suspected as one of the virulence factors [7].
NADase has the ability to cleave β-NAD+, which is uni-
versally important in numerous essential redox and
energy-producing biological reactions, depleting intracel-
lular NAD pools [8,9]. NADase is also toxic for bacterial
cells themselves, therefore, GAS encodes ifs gene whose
product (IFS) is an endogenous inhibitor of NADase
activity and localized in the bacterial cytoplasmic com-
partment [9,10]. NADase precursor exists as an inactive
complex with IFS [9,10]. In vitro, intoxication of keratino-
cytes with NADase was associated with cytotoxic effects
[11,12]. Bricker et al. presented that NADase enhances
GAS virulence in vivo using mouse models [13]. These
results enabled us to further study the NADase as a target
molecule to reduce GAS virulence. However, another
study of GAS infection among aboriginal people in Aus-
tralia found no relationship between NADase production
and severity or outcome of GAS infection [14]. Further-
more, we recently reported that M-1 group A streptococ-
cal isolates were divided into three groups based on
NADase activity: high activity, low activity and no activity
[15], whereas we did not find that low and high levels of
the NADase activity correlated with severity of GAS
human infection (data not shown). Meanwhile, Ajdic et
al. reported that among 73 strains isolated from patients
with mostly invasive GAS infections from a recent out-
break of streptococcal infection, 67 (92%) were NADase
producer [16], although strains isolated from patients
with non-invasive GAS infections were not assayed. It is
unknown why the 8% strains isolated from patients with
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mostly invasive GAS infections were not NADase pro-
ducer. Therefore, we thought that before taking up the
study of our interest, it should be further determined how
NADase is important as a virulence factor for severe
invasive disease. We mainly focused on the following two
points: (i) How do NADase activity levels correlate with
virulence? (ii) If NADase is important for severe invasive
disease, and whether it is possible that IFS suppresses the
severity. In this study, we present further evidences to
prove the importance of NADase in severe invasive dis-
ease.
Methods
Bacterial strains
Streptococcal strains were isolated as causative organ-
isms from invasive diseases patients in Japan (Table 1). S.
pyogenes (GAS) strain SF370, which is prevalent as the
database reference isolate (accession NC_002737), was
provided by the courtesy of J. J. Ferretti [17,18]. Strepto-
coccal strains were cultured in brain heart infusion (E-
MC62, EIKEN Chemical Co., Tokyo, Japan) supple-
mented with 0.3% yeast extract (BD, Sparks, MD, USA)
(BHI-Y) broth unless otherwise described.
Quantitation of NADase activity in bacterial supernatant
NADase activity was determined by the method of Ste-
vens et al. [19] as described previously [15].
Construction of the recombinant His-IFS and His-TarC 
proteins
The ifs gene of pGST-NgaGT01 (IFS) [15] was amplified by
PCR with Extaq DNA polymerase (Takara Bio, Ohtsu,
Japan) using primers IFS-F (BamHI) (5'-AGGAAG-
TAACGGATCCTATAAGGTGC-3') and IFS-R (5'-
ATGTGTCAGAGGTTTTCACCG-3'). Oligonucleotide
IFS-F(BamHI) contained a restriction site for BamHI
(shown in bold in the primer sequence). The amplifica-
tion product, which contained a restriction site for SalI,
was digested with BamHI and SalI, and cloned into pQE-
80L (Qiagen, Hilden, Germany) to yield pHis-IFS, whose
insert was sequenced.
Plasmid pHis-TarC encoding a His-tagged carboxyl ter-
minal domain of an Escherichia coli aspartate chemore-
ceptor (named as His-TarC) was constructed by
subcloning a 1.1 kb KpnI fragment of pIT6 [20] into pQE-
80L.
Purification of the recombinant His-tagged proteins
The His-tagged IFS fusion protein was induced and puri-
fied under native conditions as described in the manufac-
ture's protocol (Qiagen), with the following modification.
T o induce the His-IFS fusion protein, 1 mM IPTG was
added to a logarithmic-phase culture of E. coli JM109/
pHis-IFS and shaken for 3 h at 37°C. A total of 100 ml of
the liquid culture was transferred to a centrifuge tube and
centrifuged to sediment the cells. The pellet was resus-
pended in 10 ml ice cold PBS + 1% Triton X-100. After a
freeze (-80°C)/thaw and a sonication at 170 W for 2 min
(Insonator 201M, Kubota, Tokyo, Japan), insoluble mate-
rial was removed by spinning it at full speed (16 000 g) for
10 min. One ml of the 50% Ni-NTA slurry was washed
twice with 4 ml of Milli-Q water, equilibrated with 1 ml of
PBS + 1% Triton X-100, added to the 10 ml cleared lysate
and mixed gently by rotating at room temperature for 20
min. The lysate-Ni-NTA mixture was loaded into a col-
umn and washed three times with 4 ml wash buffer. The
protein was eluted with PBS + 250 mM Imidazole. The
protein was verified using SDS-PAGE and anti-RGS-His
antibody (Qiagen) or by dose-dependent inhibition of
NADase activity of both GAS culture and the GST-Nga
fusion protein constructed in a previous report [15].
Table 1: M-1GAS clinical isolates used in this study
Isolates place# Isolated year
SF370 America 1985
1529 Japan (Chiba) 1990-2000
KN01 Japan (Aichi) 1990-2000
MDYK Japan (Aichi) 2000 ~
MUY Japan (Mie) 2000 ~
GT01 Japan (Gunma) 2000 ~
FI01 Japan (Fukushima) 2000 ~
CR01 Japan (Aichi) 2000 ~
IYAT Japan (Fukushima) 2000 ~
All isolates, except for SF370, are derived from invasive diseases.
# Japanese Cities were described in parenthesis.Tatsuno et al. BMC Microbiology 2010, 10:144
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The His-TarC was induced and purified by the same
method described above. In addition, characterization by
SDS-PAGE confirmed that the IPTG-dependently
induced recombinant protein was purified as essentially a
single band of the expected size (31 k Dalton) (data not
shown).
Mouse model of invasive skin tissue infection
All animal studies have complied with federal and institu-
tional guidelines. The ability of S. pyogenes to cause local
skin lesions and necrosis in mice after skin inoculation
was assessed using a procedure similar to that described
elsewhere [21]. In brief, 3-week-old female ICR mice (10-
12 g) were anesthetized by ketamine-xylazine injection,
and the hair was cut from the left flank using scissors
and/or electric shaver to bare the skin, unless otherwise
indicated. Bacteria (0.1 ml; 1 × 107 cfu per mouse) grown
in BHI-Y were injected with a 27-gauge needle just under
the surface of the skin so that a superficial bleb was raised
immediately below the skin surface. The number of col-
ony-forming units injected was verified for each experi-
ment by plating bacteria on BHI-Y or sheep blood agar
plates (with or without kanamycin) and counting colony-
forming units.
The purified recombinant His-IFS or His-TarC was
injected as follows: (1) on day 0, 25 μg (per 0.1 ml) was
inoculated together with bacteria in the left flank. It was
confirmed that both His-IFS and His-TarC had no effect
on bacterial viability and growth (data not shown), and
(2) on days 2-4, 50 μg (per day) was inoculated intraperi-
toneally. The bacterial viability (and growth) was assessed
by incubating the remaining mixture of bacteria and
either His-IFS or His-TarC used on the day 0 for 1 to 6
hours, and counting colony-forming units on BHI-Y or
sheep blood agar plates. Because it is difficult to increase
injection volume in the skin, we decided to increase the
concentration of IFS per ml of injection solution. Prelimi-
nary test showed highest concentration (no dilution) was
more effective at reducing GAS virulence than any of the
IFS dilutions tested (data not shown). Thus, we used the
highest concentration to add as much IFS as our possible.
Creation of nga mutant of strain GT01
Escherichia coli JM109 was used to propagate plasmid
constructions. Non-polar inactivated mutant of nga was
constructed via double-crossover allelic replacement in
the chromosome of S. pyogenes GT01. To construct the
plasmid for the nga knockout mutant, the 5' end of nga
(fragment 1) was amplified with oligonucleotide primers
ngaGT-n1 (5'-GGCTAGCGAACAGATGTGAAGGT-
TCTG-3') with an NheI restriction site and ngaGT-c1 (5'-
TCCCCCGGGTTTCTCATGTAAACCACCT-3') with
an SmaI restriction site, and the 3' end of nga (fragment
2) was amplified with ngaGT-n2 (5'-TCCCCCGGGA-
TAGGAAGTAACAATATGT-3') with an SmaI restric-
t i o n  s i t e  a n d  n g a G T - c 2  ( 5 ' - GG ACTAGTATGTTAGCT
TTCAATTGGGT-3') with an SpeI restriction site. Oligo-
nucleotides ngaGT-n1, ngaGT-c1, ngaGT-n2 and ngaGT-
c2 contained a restriction site for NheI, SmaI, SmaI and
SpeI ,  r e s p e c t i v e l y ,  ( s h o w n  i n  b o l d  i n  t h e  p r i m e r
sequence). Fragment 2 was digested with SmaI and SpeI
for insertion into multi-cloning site 2 of the pFW12 plas-
mid [22]. The resulting plasmid was then digested with
NheI and SmaI, and both the spc2 DNA fragment con-
taining  aad9  (promoterless spectinomycin resistant
gene), which was obtained from a SmaI digested frag-
ment of pSL60-2 [23], and the NheI-SmaI-digested frag-
ment 1 were inserted. This plasmid, nga::aad9/pFW12,
was a suicide vector for S. pyogenes. For the preparation
of competent cells, strain GT01 was harvested at early- to
mid-log phase (OD660 = 0.4 to 0.5) and washed twice with
0.5 M sucrose buffer. The constructed suicide vector
nga::aad9/pFW12 was transformed into strain GT01 by
electroporation. The conditions of electroporation were
1.25 kV/mm, 25 μF capacitance and 200 Ω resistance,
using Gene Pulser II (Bio-Rad, Hercules, CA, USA). After
incubation at 37°C for 3 h, competent cells were spread
onto BHI agar plates containing 0.3% yeast extract and
spectinomycin (final concentration 100 μg/ml). Selected
colonies on the plates were cultured. Cultured bacteria
wer e was hed once wit h saline, resuspended in 10 mM
Tris, 1 mM EDTA and boiled for 10 min. Genomic DNA
was obtained from the supernatant of boiled bacteria.
The double-crossover replacement was analyzed using
genomic DNA by PCR and successful double-crossover
replacement was further confirmed by DNA sequencing.
Cloning of nga gene
All PCR reactions for plasmid construction were under-
taken as previously described [15].
The ngaGT01 of S. pyogenes strain GT01 was amplified
by PCR with Extaq DNA polymerase using primers nga-
n4Eco (5'-GGAATTCATGAGAAACAAAAAAGTAAC-
3') and sloC2 (5'-ATCATCCGTTTTCTGACCTG-3') and
cloned into pGEM-T easy (Promega, Madison, WI, USA)
to yield pNGIe1, whose insert was sequenced. Oligonu-
cleotide nga-n4Eco contained a restriction site for EcoRI
endonuclease (shown in bold in the primer sequence).
The ngaGT01 gene is oriented in the opposite direction as
the lacUV5 promoter. An EcoRI fragment containing the
ngaGT01 gene of pNGIe1 was sub-cloned into pLZ12-Km2
[24] to yield pLZN2, whose insert was sequenced for ver-
ification.
To construct pLZN-RBS, inverse PCR with Pyrobest
DNA polymerase (Takara) using the primers LZ-R0 (5'-
CCGTCGACCTCGAGGGGGGGC-3') and nga-RBS1
(5'-CCGCTCGAGATATAAGGTGGTTTACAT GAG ATatsuno et al. BMC Microbiology 2010, 10:144
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AACAAAAAAGTAAC-3') was performed to add a
potential ribosome-binding site (16 bp) to nga encoded
on pLZN2. Oligonucleotides nga-RBS1 and LZ-R0 con-
tained a restriction site for XhoI endonuclease, the poten-
tial ribosome binding site and/or start codon for the nga
gene, respectively (shown in bold, underline and italic in
the primer sequence, respectively). The amplification
product was digested with XhoI and self-ligated. The
insert was sequenced for verification.
To construct pLZN-RBSII2, inverse PCR with Prime-
STAR™ HS DNA polymerase (Takara) using the primers
nga-RBS2 (5'-CCGGGGCCCTTAAAAATAATATAAG
GTGGTTTACATGAG-3') and LZ-R3 (5'-CTCGAG-
GGGGGGCCCATCAGTC-3') was performed to add the
further upstream DNA sequence (10 bp) to the potential
ribosome-binding site encoded on pLZN-RBS. A oligo-
nucleotide nga-RBS2 contained the upstream DNA
sequence, the potential ribosome binding site and start
codon for the nga  g e n e  ( s h o w n  i n  d o t t e d  u n d e r l i n e ,
underline and italic in the primer sequence, respectively).
The amplification product was self-ligated and the insert
was sequenced for verification.
Statistical analysis
The significant difference of virulence (mortality)
between low and high NADase activity groups was ascer-
tained as follows. The mortality of mice infected with
each GAS isolate, but not mean mortalities produced by
pooling multiple isolates into the two groups, was deter-
mined. The four mortalities in the low NADase activity
group and the four mortalities in the high NADase activ-
ity group were compared using an unpaired t test http://
www.graphpad.com/quickcalcs/ttest1.cfm.
Survival times were assessed using a log-rank compari-
son. R software was used for statistical analysis http://bio-
inf.wehi.edu.au/software/russell/logrank/. P value ≤ 0.05
was considered significant.
Results
Correlation of NADase activity levels and virulence
T h e  l e v e l s  o f  d e t e c t a b l e  N A D a s e  a c t i v i t y  p r o d u c e d  b y
clinical isolates of M-1 GAS were divided into two groups
(low-activity and high-activity) in our previous study
[15]. It is possible that isolates belonging to the high-
activity group are more virulent, possibly causing invasive
infection at higher severity and/or with lower dose. T o
investigate this possibility, we used a mouse model for the
invasive soft-tissue infection, which is currently the most
accepted available method for this type of in vivo experi-
ment. As shown in Table 2, after skin inoculation with M-
1 GAS isolates belonging to the high-activity group, 80%,
60%, 100% and 67% of the mice were dead within a week,
respectively, whereas with the isolates belonging to the
low-activity group, 29%, 33%, 67% and 17% of the mice
died, respectively (P = 0.0272 for unpaired t test). The
survival curves (Figure 1), based on the data of Table 2
showed that no mouse died after day 8 on the study.
Mouse infection model using nga knockout mutant and 
complemented strain
To investigate the extent with which NADase contributes
to GAS virulence in the mouse model, nga gene encoding
NADase of strain GT01 was replaced with an antibiotics
marker. The resulting GT01Δnga  did not show any
detectable NADase activity and mortality in the invasive
soft-tissue mouse-infection test (Table 2). Therefore, we
tried to complement the phenotype using a plasmid
pLZN2 in which only the coding region of nga is cloned.
However, the complementation study using GT01Δnga
(pLZN2) strain was not successful in restoring survival
times (Table 3). Unsuccessful complementation might be
due to insufficient NADase activity in the GT01Δnga
(pLZN2) strain (NADase activity: 1.28 ± 0.12 U). There-
fore, two additional plasmids (pLZN-RBS and pLZN-
RBSII2) were constructed containing 16 and 26 base pair
upstream DNA sequences encoding the potential ribo-
some-binding site, which is lacking in pLZN2 respec-
tively (see Materials and Methods in detail). The resultant
GT01Δnga (pLZN-RBSII2), but not GT01Δnga (pLZN-
RBS), strain enhanced virulence compared to the mutant
in the mouse model (P = 0.019 for comparison of survival
times). The result of the GT01Δnga (pLZN-RBS) strain
may also be due to the same reason that the strain was
non-functional, since it contained only slightly improved
levels of NADase activity (1.78 ± 0.03 U).
Furthermore those results encouraged us to construct
plasmids containing longer upstream DNA sequences
than what is present in pLZN-RBS and pLZN-RBSII2.
However these plasmids were not successfully con-
structed (data not shown, see Discussion in detail).
Assessment of body weight change in mouse infection 
model experiment
First, we judged the virulence based only on the mortality
rate. Although GT01Δnga  (pLZN2) and GT01Δnga
(pLZN-RBS) did not kill the injected mice (Table 3), pos-
sibly due to insufficient NADase activity, we found that
there were some mice which exhibited a poor health con-
dition but eventually survived. Hence, we also evaluated
virulence of GAS infection in mice by monitoring body
weight. In this method, lower body weight implies a more
severe form of disease. We hypothesized that the body
weight of mice injected with the complement should be
lower than those injected with GT01Δnga (pLZ12-Km2:
control vector). Our results indicated that the average
rates of increasing body weight in mice injected with the
complement strain GT01Δnga (pLZN2) were lower than
in mice injected with GT01Δnga (pLZ12-Km2), but thisTatsuno et al. BMC Microbiology 2010, 10:144
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difference was not statistically significant (data not
shown). GT01Δnga (pLZN-RBS) injection in the mouse
model showed slightly lower increasing rates of body
weight than did GT01Δnga  (pLZN2) (data not shown)
and GT01Δnga (pLZ12-Km2: control vector) (Figure 2A).
In addition, when the body weight on days 2 and 3 post-
infection was analyzed, GT01Δnga (pLZN-RBSII2) with
the highest NADase activity showed the slowest increas-
ing rate of body weight (Figure 2B).
IFS-inhibition of the virulence of the GAS strain GT01
If purified IFS is able to suppress GAS virulence in the
mouse-infection model, it would support the role of
NADase in vivo. For this experiment, His-IFS was puri-
fied (Figure 3) and used in the mouse-model infection.
Meanwhile, as an unrelated protein, His-TarC which is a
His-tagged carboxyl terminal domain of an E. coli aspar-
tate receptor was used. As shown in Figure 4, the solution
containing purified His-IFS, but not the control His-
TarC, significantly reduced the virulence of GAS. The
control protein was not effective for GAS virulence (Fig-
ure 4) because the mortality and the survival times did
not decrease and prolong, respectively, compared with
the result of GT01 infection without treatment (see GT01
strain in Table 2 for comparing the mortalities, data not
shown for survival times).
Discussion
Recent reports have suggested that NADase is important
for enabling GAS to cause invasive disease [13,19]. These
reports created our interest in NADase as a target mole-
cule to reduce the GAS virulence. However, before study-
ing the ability of a NADase-inhibitor to reduce GAS
virulence, we felt NADase itself should be further charac-
terized in its virulence causing role based on the follow-
ing two reasons. (i) In M type-3 clinical isolate used in the
previous study, the difference between mortality of mice
infected with the nga strain and the parental strain was
about only 25% [13]. Meanwhile, we recently reported
that M-1 group A streptococcal isolates are divided into
three groups based on NADase activity: high activity, low
activity and no activity [15]. If a high-activity isolate is
used to measure mortality of mice infected with GAS
compared with the nga  strain, the difference could be
Table 2: Virulence (Mortality) to mouse of GAS isolates with different NADase activity
NADase Isolate Mortalitya (Death/Trial) NADaseb
Low activity 1529
KN01
MDYK
MUY
29% (2/7)
33% (3/9)
67% (4/6)
17% (1/6)
3.37 ± 0.66
6.19 ± 0.52
2.95 ± 0.26
2.97 ± 0.95
High activity GT01
FI01
CR01
IYAT
80% (12/15)
60% (6/10)
100% (12/12)
67% (4/6)
57.03 ± 3.65
59.40 ± 4.76
114.30 ± 8.67
87.25 ± 5.22
No activityc GT01 nga
SF370
0% (0/8)
17% (1/6)
0.49 ± 0.13
-0.44 ± 0.80
a, Mortality was determined on Day 11.
b, NADase activity (units) ± standard error are indicated. One unit of NADase activity is defined as the amount (μg) of β-NAD cleaved per hour 
per μl culture supernatant as described previously [15].
c, Strain SF370, which encodes an inactive form of Nga [15] was added as negative control.
Figure 1 Survival after skin inoculation with GAS isolates with dif-
ferent NADase activities. The survival times of 28 and 43 mice infect-
ed with GAS isolates belonging to low- and high-activity groups in 
Table 2, respectively, were shown. In addition, the survival time of mice 
infected with strain SF370 belonging to the no-activity group was also 
shown as a reference, since it is possible that the old strain differs con-
siderably in genetic background compared with the other more con-
temporary eight isolates of Table 2 as described previously [7].
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wider than if a low activity isolate were used. Indeed, in
this study, we found that the difference between mortali-
ties of mice infected with GT01 (12/15 = 80% death), a
high-activity isolate, and the GT01Δnga (0/8 = 0% death)
was 80% (see Table 2). In addition, the difference in mice
mortality between the cases of GT01 (pLZ12-Km2, vec-
tor plasmid) and GT01Δnga (pLZ12-Km2) was 73% (see
Table 3). This result shows that the GT01 isolate could
provide an advantage compared with the M type-3 clini-
cal isolate when studying the ability of a NADase-inhibi-
tor to reduce GAS virulence, which is our original
interest. (ii) To our knowledge, the reduced virulence of
the nga-deletion mutant of GAS has never been success-
fully complemented using a cloned nga gene. It is com-
mon knowledge that complementation tests in vivo are
not easily accomplished due to increased technical prob-
lems when compared to an in vitro study. In such cases,
some alternative methods can be used. For example,
Bricker et al. [13] constructed two independent nga-defi-
cient mutants and showed that they have similar pheno-
t y p e s .  I n  t h i s  s t u d y ,  w e  a d d e d  t w o  m o r e  p o i n t s  o f
supportive data. We showed that an nga knockout GAS
strain possessing a cloned nga gene partially restored vir-
ulence (Figure 2 and Table 3). In addition, we showed that
a solution containing purified IFS suppressed the viru-
lence of GAS in the experimental mouse-infection model
(see later for additional discussion).
Although the data of Table 2 support our conclusion
described earlier, some of the individual data were incon-
sistent with each other. For example, some of the strains
belonging to low- and high-activity groups showed simi-
lar survival curves. However, this is not surprising
because multiple factors play a role in GAS virulence, and
the productions of virulent factors differ among the
strains [25]. Therefore, it is important to compare groups
including multiple, but not single, strains.
Regarding Nga knockout mutant and complementa-
tion, the NADase activity for the GT01 strain carrying
the pLZ12-Km2 vector was different from that of GT01
alone (reported in Tables 2 and 3). Indeed, the virulence
between the two strains also appears to be slightly differ-
ent from each other, although we were unable to explain
the reason.
Although the plasmid pLZN-RBSII2 conferred signifi-
cant virulence to the nga strain when compared to a con-
trol vector (Table 3 and Figure 2), we found that the strain
nga  (pLZN-RBSII2) produced only 8% of the NADase
activity found in the wild type strain. In order to restore
NADase levels to near normal, we attempted to construct
plasmids containing longer upstream DNA sequences
than what is present in pLZN-RBS and pLZN-RBSII2.
However these plasmids were not successfully con-
structed, possibly due to the potential toxicity of over
produced NADase to bacterial cell.
As shown in Figure 4, injection of NADase inhibitor
(His-IFS) significantly rescued mice from strains GT01.
To further investigate the potential of the His-IFS solu-
tion, we tested strain CR01, which showed the highest
virulence in the mouse-infection model among our col-
lected strains (see Table 2). Although His-IFS alone was
not sufficient to significantly rescue mice from the strain
CR01, a combination of His-IFS solution and ampicillin
was able to significantly decrease GAS virulence in mice
compared with ampicillin alone (unpublished data).
These results also show that NADase activity occurs in
vivo and can be inhibited.
Using western blot analysis, we detected two bands
from pHis-IFS using anti-RGS-HIS antibody (Figure 3).
Based on the specificity of this antibody, we attributed
the smaller band to degradation of the His-IFS protein.
The higher virulence of strain CR01 when compared to
the other isolates belonging to high activity group (Table
2) may not only be due to higher level of NADase activity,
but also due to additional unknown factors. For example,
two-dimensional gel electrophoresis demonstrates that
CR01 presents a different pattern of secreted extracellular
proteins compared to the other isolates belonging to high
activity group, including markedly lower level of the SpeB
protein (unpublished results). Further analysis of the
strain CR01, although the less representative strain
Table 3: Virulence (Mortality) to mouse of GT01 nga with or without cloned nga gene
Strain Mortalitya NADaseb
GT01 (pLZ12-Km2, vector)  73% (8/11) 14.12 ± 1.30
GT01 nga  (pLZ12-Km2, vector) 0% (0/17) 0.04 ± 0.06
GT01 nga (pLZN2, nga) 0% (0/11) 1.28 ± 0.12
GT01 nga  (pLZN-RBS, nga) 0% (0/10) 1.78 ± 0.03
GT01 nga  (pLZN-RBSII2, nga) 29% (4/14) 4.57 ± 0.17
Bacteria were cultured in BHI-Y broth supplemented with kanamycin (100 μg/ml).
a, Mice were observed for 8 days, because no mouse died after day 8 on previous study (see Figure 1).
b, NADase activity was determined as described in Table 2.Tatsuno et al. BMC Microbiology 2010, 10:144
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among the high activity isolates had not been focused on
v e r y  m u c h  i n  t h i s  s t u d y ,  w o u l d  b e  a  v e r y  i n t e r e s t i n g
advance for the field.
Finally, we should discuss the discrepancy between
NADase activity being important to the virulence of S.
pyogenes during in vivo mouse models and our epidemio-
logical data showing that low and high levels of NADase
activity do not correlate with the severity of the S. pyo-
genes isolates in human infection. One possibility is that
there is no statistical difference due to low sample num-
ber which is a result of a very small number of cases of the
STSS disease. There is another possibility. After human
passage, the isolated S. pyogenes could be different from
the original strain which caused the infection due to get-
ting genetic mutations. It is difficult to directly confirm
the virulence of the passed isolates, since humans are the
Figure 2 Virulence (based on body weight change) to mouse of GT01Δnga with or without cloned nga gene. (A) The change in body weight 
(% of the first weight) post-infection was shown in a week (* as a reference, the parental strain was shown in three days, because most mice died within 
this period). (B) Relationship of body weight and NADase activity was shown on days 2 and 3. NADase activities (0.04, 1.28, 1.78 and 4.57 U, respectively) 
of (a) GT01Δnga (pLZ12-km2), (b) GT01Δnga (pLZN2), (c) GT01Δnga (pLZN-RBS) and (d) GT01Δnga (pLZN-RBSII2) was plotted on the horizontal axis, 
respectively (see Table 3 or the text for NADase activity of each strain). The gradual increase in body weight (%) depended on higher NADase activity 
of the strains. The error bars indicate the standard error of the means.
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only natural hosts for the organism. When dealing with
organisms, which lack a non-human natural host, we can
never be perfectly certain and therefore must rely on
additional accumulated supportive (usually indirect) evi-
dence. If our purified His-IFS (NADase inhibitor) is able
to rescue STSS patients in future that could provide a
more ethically acceptable form of direct evidence.
Conclusions
We have presented further supportive evidence that
NADase is important for severe invasive disease of S. pyo-
genes in vivo using the experimental mouse model. Fur-
thermore, we provided useful evidence that the NADase
is the potential target to suppress the virulence.
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Figure 4 Inhibition of the mortality in mouse of a GAS GT01 clini-
cal isolate by His-IFS. The solution including His-IFS reduced the vir-
ulence of the GAS to 42% mortality (5 death/12 trial) compared with 
83% (10/12) of the control His-TarC (P = 0.008 for comparison of surviv-
al times).
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